worsening migraines / extremely painful incapacitating headaches/ photophobia; short-term memory loss; anxiety attacks; hair loss; autonomic, autoimmune and neurological injuries; inability to sleep; numbness in his extremities; tingling in his extremities; autonomic, autoimmune and neurological injuries; vertigo; dizziness; autonomic injuries/ autonomic dysfunction; 2nd dose of Gardasil on 30-SEP-2019, 3rd dose of Gardasil on 03-FEB-2020; 1st dose of Gardasil at the age of 35 years old; Information has been received from a lawyer regarding a case in litigation and refers to an adult male patient (exact age not provided). His concurrent conditions, medical history and concomitant therapies were not provided. On 01-AUG-2019, at the age of 35 years old (Product administered to patient of inappropriate age), the patient received the first dose of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) (dose, route of administration, anatomical location, lot # and expiration date were not provided), for prophylaxis. On 30-SEP-2019, he was administered the second dose of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) (dose, route of administration, anatomical location, lot # and expiration date were not provided), for prophylaxis, administered by physician. On 03-FEB-2020, the patient received the third dose of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) (dose, route of administration, anatomical location, lot # and expiration date were not provided), for prophylaxis administered by physician (Inappropriate schedule of product administration). On an unknown date, he experienced serious autoimmune, autonomic and neurological injuries as a result of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL). On an unknown date, reported as following Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) injections, the patient experienced extremely painful and incapacitating headaches to the point he was unable to do many of his daily activities. As the months progressed, so did the patient's symptoms, including but not limited to worsening migraines, anxiety attacks, short-term memory loss, inability to sleep, photophobia, dizziness, vertigo, numbness and tingling in his extremities, and hair loss. As a result of post - Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) symptoms, he was unable to engage in activities that a person his age would normally enjoy and had difficulty functioning in his daily life. As a proximate result of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL), the pt suffered and continued to suffer severe and permanent physical injuries, and associated symptomology and suffered severe and permanent emotional injuries, including pain and suffering. He also had a substantial fear of suffering additional and ongoing harms, including but not limited to being at an increased risk of cancer, and future symptoms and harms associated with his injuries caused by Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL). As a direct and proximate result of his Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL)-induced injuries, he suffered and continued to suffer economic losses, including considerable financial expenses for medical care and treatment, and diminished income capacity, and he would continue to incur these losses and expenses in the future. The outcome of the events was considered to be not recovered. The reporter considered the events to be related to Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL).  Upon internal review, the event of autoimmune disorder was determined to be medically significant.  The reporter considered migraine, amnesia, anxiety, alopecia, nervous system disorder, insomnia, hypoaesthesia, paraesthesia, vertigo, and dizziness to be disabling events.